Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV001195303 | SCV001365625 | likely pathogenic | Autosomal recessive spastic ataxia | 2019-04-15 | criteria provided, single submitter | clinical testing | The p.Trp3701MetfsX17 variant in SACS has not been previously reported in individuals with spastic ataxia and was absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 3701 and leads to a premature termination codon 17 amino acids downstream. This termination codon occurs within the last exon and is, therefore, likely to escape nonsense mediated decay (NMD) and result in a protein truncated by 860 amino acids (representing 19% of the full protein length). Notably, many other truncating variants in this region have been reported in the homozygous or compound heterozygous state in individuals with ARSACS. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal recessive spastic ataxia, Charlevoix-Saguenay type. ACMG/AMP Criteria applied: PVS1_Strong, PM2. |